ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Most Patients Liked Being Switched to Subcutaneous Testosterone Injections
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 254953" data-attributes="member: 13851"><p><strong>Our Experience with Subcutaneous Injection of Non-Proprietary Testosterone Cypionate as a Novel Approach for Hypogonadism (2023)</strong></p><p><em>A Spellman, K Alter, L Levine</em></p><p></p><p></p><p><strong>Abstract</strong></p><p><strong></strong></p><p><strong>Introduction</strong></p><p></p><p><em>Subcutaneous injection of testosterone has been investigated as a method of testosterone replacement therapy (TRT) in hypogonadal men. <strong>We have been investigating the use of a non-proprietary subcutaneous (SubQ) injection of testosterone cypionate using a ½ inch 27g needle for the replacement to treat hypogonadism. This is an update on our work which includes larger sample size and longer follow-up.</strong></em></p><p></p><p></p><p><strong>Objective</strong></p><p></p><p><em><strong>To assess the use of non-proprietary SubQ TRT as treatment in hypogonadal men and its effect on HCT, PSA, and patient satisfaction.</strong></em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em><strong>This study is a retrospective chart review of patients receiving SubQ TRT with a mean follow-up length of 9.8 months (range 0-24 months). </strong>Patient data were collected prior to the initiation of therapy and at subsequent visits. Testosterone, HCT, and PSA were determined through regular blood draws and a patient satisfaction survey was performed over the phone. Univariate analysis and paired t-tests were used to analyze study variables.</em></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em>41 total patients received SubQ TRT.<strong> Mean changes in total testosterone level (increased 281.3 + 81.1, p-value=0.0008), hematocrit (increased 1.5 + 1.0), PSA (increased 0.4 + 0.4), SHIM score (increased 3.8 + 1.4, p-value=0.0088) and AUA symptom score (decreased 0.9 + 1.6) were calculated at the patients’ initial visit and most recent follow up while still on SubQ TRT (Table 1).</strong> A total of 30 patients had been on various combinations of TRT before switching to SubQ including IM (13), CC (13) Testopel (8), HCG (2) SubQ (2), T gel (1) and Anastrozole (1). <strong>Data on the most frequent TRTs are demonstrated in Table 2. Patient satisfaction surveys were completed by 32 patients (78%), with 26 (81.2%) patients reporting overall satisfaction with SubQ TRT versus 45% (9/20) with past forms of TRT. 93.7% (15/16) reported SubQ TRT was both easier and less painful, and 73.6% (14/19) preferred SubQ injections over their previous form of TRT. </strong>Reasons for stopping SubQ TRT included unrelated stroke (1), prostate cancer (1), development of scar tissue (1) or bruising<strong> (1), ineffective therapy</strong> (1), difficulty drawing up the syringe (1), cost (1), and trouble obtaining medication from the pharmacy (1).</em></p><p></p><p></p><p><strong>Conclusions</strong></p><p></p><p><em><strong>The use of non-proprietary testosterone cypionate SubQ as a treatment for hypogonadism results in an elevation in serum total testosterone and improvement in both SHIM and AUA symptom scores at follow-up. PSA and HCT rose over the span of treatment, but the rises were not statistically significant, and no patient developed erythrocytosis. Our data demonstrate SubQ TRT is easier and less painful to use and scores higher on overall patient satisfaction compared to other forms of TRT.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 254953, member: 13851"] [B]Our Experience with Subcutaneous Injection of Non-Proprietary Testosterone Cypionate as a Novel Approach for Hypogonadism (2023)[/B] [I]A Spellman, K Alter, L Levine[/I] [B]Abstract Introduction[/B] [I]Subcutaneous injection of testosterone has been investigated as a method of testosterone replacement therapy (TRT) in hypogonadal men. [B]We have been investigating the use of a non-proprietary subcutaneous (SubQ) injection of testosterone cypionate using a ½ inch 27g needle for the replacement to treat hypogonadism. This is an update on our work which includes larger sample size and longer follow-up.[/B][/I] [B]Objective[/B] [I][B]To assess the use of non-proprietary SubQ TRT as treatment in hypogonadal men and its effect on HCT, PSA, and patient satisfaction.[/B][/I] [B]Methods[/B] [I][B]This study is a retrospective chart review of patients receiving SubQ TRT with a mean follow-up length of 9.8 months (range 0-24 months). [/B]Patient data were collected prior to the initiation of therapy and at subsequent visits. Testosterone, HCT, and PSA were determined through regular blood draws and a patient satisfaction survey was performed over the phone. Univariate analysis and paired t-tests were used to analyze study variables.[/I] [B]Results[/B] [I]41 total patients received SubQ TRT.[B] Mean changes in total testosterone level (increased 281.3 + 81.1, p-value=0.0008), hematocrit (increased 1.5 + 1.0), PSA (increased 0.4 + 0.4), SHIM score (increased 3.8 + 1.4, p-value=0.0088) and AUA symptom score (decreased 0.9 + 1.6) were calculated at the patients’ initial visit and most recent follow up while still on SubQ TRT (Table 1).[/B] A total of 30 patients had been on various combinations of TRT before switching to SubQ including IM (13), CC (13) Testopel (8), HCG (2) SubQ (2), T gel (1) and Anastrozole (1). [B]Data on the most frequent TRTs are demonstrated in Table 2. Patient satisfaction surveys were completed by 32 patients (78%), with 26 (81.2%) patients reporting overall satisfaction with SubQ TRT versus 45% (9/20) with past forms of TRT. 93.7% (15/16) reported SubQ TRT was both easier and less painful, and 73.6% (14/19) preferred SubQ injections over their previous form of TRT. [/B]Reasons for stopping SubQ TRT included unrelated stroke (1), prostate cancer (1), development of scar tissue (1) or bruising[B] (1), ineffective therapy[/B] (1), difficulty drawing up the syringe (1), cost (1), and trouble obtaining medication from the pharmacy (1).[/I] [B]Conclusions[/B] [I][B]The use of non-proprietary testosterone cypionate SubQ as a treatment for hypogonadism results in an elevation in serum total testosterone and improvement in both SHIM and AUA symptom scores at follow-up. PSA and HCT rose over the span of treatment, but the rises were not statistically significant, and no patient developed erythrocytosis. Our data demonstrate SubQ TRT is easier and less painful to use and scores higher on overall patient satisfaction compared to other forms of TRT.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Most Patients Liked Being Switched to Subcutaneous Testosterone Injections
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top